FDA Commissioner Ousted Amidst Turmoil and Policy Clashes

• Dr. Marty Makary's resignation as FDA Commissioner concludes a period marked by internal strife and policy disagreements.
• President Trump is expected to appoint Kyle Diamantas, who previously worked as the top food official at the FDA, to step in as acting commissioner.
• Makary's tenure saw clashes over drug approvals, including rare disease treatments, and policy initiatives like flavored vapes and abortion pill access.
• The pharmaceutical industry expresses concern over the leadership change as Prescription Drug User Act Fee negotiations loom.

Good News, Everyone: Makary's Out

As a professor of things that make you say, "Wha?", I've seen some strange happenings in my time. But this FDA business… oh, my. Apparently, Dr. Marty Makary, the head honcho at the Food and Drug Administration, has been given the boot. Yes, like a forgotten vial of Slurm, he's been tossed out. According to the news, President Trump himself indicated that Kyle Diamantas, who previously worked as the top food official at the FDA, will step in as acting commissioner. I always say, "Sometimes good news comes in a confusing package".

Slow-Walking Vapes and Abortion Pills

The reports suggest Makary was a bit sluggish on some of Trump's pet projects, like legalizing flavored vapes. Flavored vapes I say. That sounds like something Zoidberg would enjoy before his hunger sets in. And then there's the whole abortion pill kerfuffle. Apparently, he wasn't exactly rushing to review the safety of mifepristone. Which reminds me of that time I invented a pill that made you forget you took it. The White House isn't happy when things are slow-walked. It is important to note that the White House have in the past taken decisive actions regarding prediction markets, as seen in the article: White House Warns Staff No Prediction Market Shenanigans. It appears that a consistent approach to internal policy is maintained regardless of the specific issue.

FDA Morale: Lower Than a Bender's Bank Account

And it seems things weren't all sunshine and rainbows inside the FDA itself. Staff morale has apparently plummeted. Layoffs, departures of key scientists, and general distrust in leadership. It's a recipe for disaster. Even that Pazdur fellow, a cancer regulator of some renown, left because of Makary's leadership. As I always say, "When faced with a difficult decision, always ask: What would a Bender do?" and then do the opposite.

Industry Jitters

The pharmaceutical industry is apparently a bit nervous about all this upheaval. They are currently negotiating the reauthorization of the Prescription Drug User Act Fee. That's a fancy way of saying they pay the FDA to review their drugs. It's like paying Bender to be your accountant – you know it's going to be a mess, but you do it anyway. This whole scenario is reminding me of the time I tried to regulate the universe's supply of dark matter. It ended predictably: badly.

The Prasad Predicament

Then there's this Vinay Prasad character, one of Makary's appointees. Seemingly, he was in charge of vaccines and biotech treatments before leaving the agency himself. Criticism mounted after the FDA rejected Moderna's flu shot, and Prasad faced backlash for rejecting a Huntington's disease gene therapy from uniQure. This is reminding me of my time spent researching the effects of time travel on the human digestive system. The results were… explosive.

Science vs. Politics: A Timeless Battle

Ultimately, it seems this whole situation boils down to the age-old struggle between science and politics. Senator Ron Johnson is even launching an investigation into the FDA's rejection of rare disease treatments. To install a new commissioner, Trump needs the support of Senator Bill Cassidy, which is no easy task. Now, I'm no politician, but I do know a thing or two about manipulating the space-time continuum. Perhaps I should offer my services. Although, last time I did that, I created an alternate universe where everyone had two noses. On second thought, maybe not.